YieldMax MRNA Option Income Strategy ETF
MRNY (AMEX)
YieldMax MRNA Option Income Strategy ETF (MRNY) targets generating monthly income through call options on Moderna (MRNA) stock. Despite a striking annual yield of over 77.5%, the fund has faced significant challenges, reflected in its 1-year and 5-year returns of -57.45% and -90.08%, respectively. Investors should be cautious, as the fund’s expense ratio of 1.27% is notably higher than the category average, raising concerns about overall profitability.
Pros:
- High dividend yield
- Monthly income generation
Cons:
- Significant risk of capital loss
- High expense ratio
The YieldMax MRNA Option Income Strategy ETF (MRNY) may be suitable for investors seeking high income through options strategies, particularly those with a tolerance for risk and volatility. However, potential investors should carefully consider the fund's significant historical losses and elevated expense ratio before committing capital.